{"id":"tpo-ra-discontinuation","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia (platelet count decline)"},{"rate":null,"effect":"Bleeding risk"}]},"_chembl":{"chemblId":"CHEMBL2107816","moleculeType":"Small molecule","molecularWeight":"293.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thrombopoietin receptor agonists (Tpo-RAs) such as romiplostim and eltrombopag stimulate megakaryopoiesis and platelet production by activating the thrombopoietin receptor. Discontinuation of these agents results in a gradual decline in platelet production as the pharmacological stimulus is removed, returning patients to their baseline platelet-generating capacity. This is a management strategy rather than a therapeutic agent itself.","oneSentence":"Tpo-RA discontinuation refers to the cessation of thrombopoietin receptor agonist therapy, allowing platelet counts to normalize after treatment withdrawal.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:13:22.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management strategy for patients previously treated with thrombopoietin receptor agonists for immune thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT05438875","phase":"PHASE3","title":"The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2022-10-12","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":96},{"nctId":"NCT03119974","phase":"PHASE4","title":"Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-26","conditions":"Persistent or Chronic ITP","enrollment":48},{"nctId":"NCT06478537","phase":"PHASE2","title":"TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-06-20","conditions":"Immune Thrombocytopenia","enrollment":56},{"nctId":"NCT05350956","phase":"PHASE2","title":"A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-06-01","conditions":"Tumor Therapy-related Thrombocytopenia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tpo-RA discontinuation","genericName":"Tpo-RA discontinuation","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tpo-RA discontinuation refers to the cessation of thrombopoietin receptor agonist therapy, allowing platelet counts to normalize after treatment withdrawal. Used for Management strategy for patients previously treated with thrombopoietin receptor agonists for immune thrombocytopenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}